(Q57226639)

1

0 references

Jun Soo Jung

2

0 references

Dong Ho Kim

3

0 references

Jung Sub Lim

4

0 references

Min Suk Kim

5

0 references

Chang-Bae Kong

6

0 references

Won Seok Song

7

0 references

Wan Hyeong Cho

8

0 references

Dae-Geun Jeon

9

0 references

Soo-Yong Lee

10

0 references

Jae-Soo Koh

Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy

11

0 references

language of work or name

English

0 references

publication date

May 2011

0 references

published in

Pediatric Blood Cancer

0 references

volume

56

0 references

issue

5

0 references

page(s)

738-43

0 references

cites work

1 reference

Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome

21 January 2018

1 reference

High-dose therapy with autologous stem cell rescue for pediatric sarcomas

21 January 2018

1 reference

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

21 January 2018

1 reference

Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials

21 January 2018

1 reference

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

21 January 2018

1 reference

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

21 January 2018

1 reference

Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas

21 January 2018

1 reference

Emerging therapeutic targets in breast cancer bone metastasis

21 January 2018

1 reference

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

21 January 2018

1 reference

Biology of breast cancer bone metastasis

21 January 2018

1 reference

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

21 January 2018

1 reference

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

21 January 2018

1 reference

Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption

21 January 2018

1 reference

Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B.

21 January 2018

1 reference

Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma.

21 January 2018

1 reference

Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells

21 January 2018

1 reference

Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases

21 January 2018

1 reference